Chiasma to Participate in the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Chiasma, a biopharmaceutical company, will present an overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on demand starting at 7:00 am on March 9, 2021. Chiasma focuses on developing oral therapies to improve treatments for rare chronic diseases. Notably, the company received FDA approval for MYCAPSSA, the first oral somatostatin analog, for acromegaly patients who have tolerated prior injectable treatments. For more details, visit www.chiasma.com.

News Market Reaction – CHMA

+1.01%

+1.01% Session move

In the trading session that priced this news, CHMA gained 1.01%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEEDHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9^th - Wednesday, March 10^th, 2021.

The presentation will be available on demand on H.C. Wainwright’s conference portal beginning at 7:00 am on Tuesday, March 9^th, 2021.

About Chiasma
Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE^®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at www.chiasma.com.

Investor Relations and Corporate Communications:
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com 

Media Relations:
Patrick Bursey
LifeSci Communications
646-876-4932
pbursey@lifescicomms.com 

FAQ

What is Chiasma presenting at the H.C. Wainwright Global Life Sciences Conference 2021?

Chiasma will present a company overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

When will the Chiasma presentation be available on demand?

The presentation will be available on demand starting at 7:00 am on March 9, 2021.

What is MYCAPSSA and its significance for Chiasma?

MYCAPSSA is the first oral somatostatin analog approved by the FDA, used for treating acromegaly patients who have tolerated injectable treatments.

What is the focus of Chiasma's drug development?

Chiasma focuses on developing oral therapies that improve treatments for rare and serious chronic diseases.

Where is Chiasma headquartered?

Chiasma is headquartered in Needham, Massachusetts.